| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | DNMR | Stock Option | Award | $0 | +149K | $0.00 | 149K | Feb 28, 2023 | Common Stock | 149K | $2.58 | Direct | F1 | |
| transaction | DNMR | Performance Stock Award | Award | $0 | +77.5K | $0.00 | 77.5K | Feb 28, 2023 | Common Stock | 77.5K | $0.00 | Direct | F2, F3, F4, F5 |
| Id | Content |
|---|---|
| F1 | The option to purchase shares of the Issuer's Class A common stock ("Common Stock") was granted to Reporting Person on February 28, 2023 under the Danimer Scientific, Inc. 2020 Long-Term Incentive Plan (the "Plan"). Options to purchase 49,751 shares of the Issuer's Common Stock will vest and become exercisable on each of February 28, 2024, February 28, 2025 and 49,752 shares of the Issuer's Common Stock will vest and become exercisable on February 28, 2026. |
| F2 | Comprised of a performance stock award (the "PSA") granted under the Plan consisting of 77,519 performance shares of the Common Stock (the "Performance Shares"). |
| F3 | Under the PSA, the Performance Shares will be issued only if they have vested in accordance with the following vesting criteria: (i) 50% of the Performance Shares (the "Total PHA Revenue Metric Shares") will be subject to vesting upon achievement of the Total PHA Revenue metric as follows: the threshold for vesting of the Total PHA Revenue Metric Shares will be the Issuer achieving Total PHA Revenue of at least $177 million, in which event 50% of the Total PHA Revenue Metric Shares will vest, and upon the Issuer achieving Total PHA Revenue of $202 million, 100% of the Total PHA Revenue Metric Shares will vest, with pro rata vesting of the Total PHA Revenue Metric Shares for any amount of Total PHA Revenue in between such ranges (in each case without duplication); |
| F4 | (ii) 50% of the Performance Shares (the "Adjusted EBITDA Metric Shares") will be subject to vesting upon achievement of the earnings before interest, taxes, depreciation and amortization, including all adjustments made for reporting this metric in public filings ("Adjusted EBITDA") as follows: the threshold for vesting the Adjusted EBITDA Metric Shares will be the Issuer achieving Adjusted EBITDA of at least $36 million, in which event 50% of the Adjusted EBITDA Metric Shares will vest, and upon the Issuer achieving $44 million of Adjusted EBITDA, 100% of the Adjusted EBITDA Metric Shares will vest, with pro rata vesting of the Adjusted EBITDA Metric Shares for any amount of Adjusted EBITDA in between such ranges (in each case without duplication). |
| F5 | The earlier of February 28, 2026 or the Reporting Person's Termination Date (as defined in the Plan). |